Lp(a): Which Tests to Order Alongside for a Complete Cardiovascular Risk Picture

What Lp(a) Is and Why It Matters

Lipoprotein(a) is an LDL-like particle with an additional protein, apolipoprotein(a), covalently bonded to apolipoprotein B-100. That extra protein gives Lp(a) both atherogenic and prothrombotic properties, making it a dual-threat molecule in cardiovascular disease. Roughly one in five people worldwide carries levels above the commonly used 50 mg/dL threshold [1].

Unlike standard LDL cholesterol, Lp(a) concentration is overwhelmingly set by the LPA gene. Diet, exercise, and most lipid-lowering drugs barely move it. A 2010 meta-analysis published in JAMA (N=126,634 across 36 prospective studies) found that each 3.5-fold increase in Lp(a) was associated with a 1.13-fold higher risk of coronary heart disease after adjustment for conventional risk factors [2]. The 2018 AHA/ACC Multisociety Cholesterol Guideline specifically names Lp(a) ≥50 mg/dL (or ≥125 nmol/L) as a "risk-enhancing factor" that can tip an intermediate-risk patient toward statin initiation [3].

Because Lp(a) is genetically stable, the European Atherosclerosis Society (EAS) consensus statement recommends measuring it at least once in every adult's lifetime [4]. One draw. That single number then needs context, and context comes from what you order alongside it.

The Standard Lipid Panel: Your Baseline Anchor

Every Lp(a) order should include a conventional lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) if one has not been run within the prior 12 months. The standard lipid panel establishes the baseline against which Lp(a) shifts risk interpretation.

Here is the problem most patients miss. Standard LDL-C assays (Friedewald calculation or direct measurement) include the cholesterol carried inside Lp(a) particles. When Lp(a) is very high, a meaningful fraction of what the lab reports as "LDL cholesterol" is actually Lp(a)-cholesterol, not the conventional LDL your statin is designed to lower. The estimated Lp(a)-cholesterol correction is roughly Lp(a) in mg/dL multiplied by 0.30 [5]. A patient with an LDL-C of 130 mg/dL and an Lp(a) of 80 mg/dL may have a "corrected" LDL-C closer to 106 mg/dL. That distinction matters for treatment decisions.

Triglycerides deserve separate attention. Elevated triglycerides (≥150 mg/dL) shift LDL subclass distribution toward small dense particles, compounding the atherogenic load Lp(a) already carries [6]. Ordering triglycerides alongside Lp(a) helps your clinician decide whether addressing triglyceride-rich lipoproteins with fibrates, icosapent ethyl, or lifestyle changes should be part of the overall strategy.

Apolipoprotein B: The Single Best Partner Test

If you add only one test to Lp(a), make it apolipoprotein B. ApoB is a direct count of all atherogenic particles: LDL, VLDL remnants, IDL, and Lp(a) itself. Each of these particles carries exactly one apoB molecule, so the apoB number tells you how many atherogenic particles are circulating, regardless of how much cholesterol each one holds [7].

The 2019 ESC/EAS Dyslipidaemia Guidelines recommend apoB as a secondary treatment target, with thresholds of <100 mg/dL for moderate risk and <65 mg/dL for very high risk patients [8]. Dr. Allan Sniderman, a lipid researcher at McGill University, has argued that "apoB is the best single measure of the adequacy of LDL-lowering therapy because it captures particle number, which is the variable most closely linked to atherogenesis" [9].

When Lp(a) is elevated and apoB is also above target, total atherogenic burden is high and warrants aggressive LDL-lowering. When Lp(a) is elevated but apoB is near goal, the residual risk is narrower and largely attributable to Lp(a) alone. That distinction guides how aggressively to pursue PCSK9 inhibitors, which lower Lp(a) by approximately 20-30% in addition to their LDL-lowering effect [10].

High-Sensitivity CRP: Measuring the Inflammatory Amplifier

Atherosclerosis is an inflammatory disease, and Lp(a) is a particularly inflammatory lipoprotein. The oxidized phospholipids carried on Lp(a) particles activate monocytes and promote vascular inflammation [11]. High-sensitivity CRP (hs-CRP) captures systemic inflammation and adds independent prognostic information on top of lipid levels.

The JUPITER trial (N=17,802) demonstrated that patients with LDL-C <130 mg/dL but hs-CRP ≥2.0 mg/L benefited from rosuvastatin therapy, with a 44% relative reduction in major cardiovascular events [12]. Patients who achieve both LDL-C <70 mg/dL and hs-CRP <2.0 mg/L on statin therapy have the lowest residual risk. When Lp(a) is elevated and hs-CRP is also above 2.0 mg/L, the combination flags a patient whose inflammatory burden may warrant more intensive lipid management or, in selected cases, consideration of anti-inflammatory strategies.

A single hs-CRP measurement can be misleading during acute illness. Order it when the patient is clinically well, and confirm an elevated result with a repeat draw two weeks later.

Lipoprotein Subfractionation: NMR or Ion-Mobility Testing

Standard lipid panels report cholesterol mass. They tell you nothing about particle number or particle size. Nuclear magnetic resonance (NMR) spectroscopy and ion-mobility testing break down the lipoprotein spectrum into subclasses.

The key metric from NMR testing is LDL particle number (LDL-P). The MESA study (N=5,598) found that LDL-P predicted incident cardiovascular events more accurately than LDL-C in cases where the two metrics were discordant [13]. A patient with "normal" LDL-C but high LDL-P carries more risk than the cholesterol number suggests. When Lp(a) is elevated, checking LDL-P helps determine whether the patient has a "double hit" of high Lp(a) plus high conventional LDL particle count, or whether Lp(a) is the dominant atherogenic driver.

Small dense LDL particles (pattern B) are also worth noting on these reports. They penetrate the arterial wall more easily and are more susceptible to oxidation. Triglyceride levels above 150 mg/dL and HDL below 40 mg/dL often predict a predominance of small dense LDL [6]. For a patient with elevated Lp(a), the presence of small dense LDL particles represents compounded risk that may push the clinical team toward earlier pharmacotherapy.

Metabolic Markers: Fasting Glucose, HbA1c, and Insulin

Cardiovascular risk does not live in the lipid panel alone. Type 2 diabetes doubles cardiovascular event risk, and insulin resistance increases atherogenic particle production even before glucose levels cross diagnostic thresholds [14]. Pairing Lp(a) with fasting glucose and HbA1c identifies patients in whom metabolic dysfunction amplifies the genetic risk Lp(a) confers.

A fasting insulin level adds further granularity. Hyperinsulinemia with normal glucose indicates early insulin resistance, a state associated with increased hepatic VLDL output and higher apoB concentrations [15]. The combination of elevated Lp(a), high fasting insulin, and elevated apoB describes a patient with both genetic and metabolic drivers of atherosclerosis. These patients often benefit from aggressive lifestyle intervention targeting insulin sensitivity (structured exercise, dietary carbohydrate moderation, weight management) alongside lipid pharmacotherapy.

HbA1c also serves as a useful surveillance marker. The American Diabetes Association recommends screening every three years for adults aged 35 and older, or earlier in the presence of risk factors [16]. Running HbA1c at the same draw as Lp(a) is efficient and prevents a return visit.

Coagulation and Thrombotic Markers

Lp(a) has structural homology to plasminogen, the precursor to plasmin, which dissolves blood clots. Elevated Lp(a) may interfere with fibrinolysis by competing with plasminogen for binding sites on fibrin [17]. This prothrombotic mechanism is distinct from its atherogenic properties and helps explain why high Lp(a) is associated with both heart attacks and aortic valve stenosis.

In patients with elevated Lp(a) and a personal or family history of thrombotic events, adding fibrinogen to the lab order provides context on clot-forming potential. Fibrinogen above 400 mg/dL is associated with increased cardiovascular risk independently of lipid levels [18]. Homocysteine is another reasonable addition if there is a family history of premature cardiovascular disease or venous thromboembolism. Elevated homocysteine (above 15 µmol/L) is associated with endothelial dysfunction and a prothrombotic state [19].

These markers are not universally recommended. They are selective add-ons for patients whose history suggests thrombotic risk layered on top of Lp(a) elevation.

Thyroid Function and Hormonal Context

Hypothyroidism raises LDL-C and can modestly raise Lp(a) in some studies, although the effect on Lp(a) is less consistent than its effect on LDL [20]. Checking TSH at the same draw rules out a reversible contributor to dyslipidemia. The American Thyroid Association recommends screening adults starting at age 35, with repeat testing every five years [21].

For patients on testosterone replacement therapy or hormone replacement therapy, lipid profiles can shift. Exogenous testosterone tends to lower Lp(a) by 10-20% in hypogonadal men, one of the few interventions that moves this biomarker at all [22]. Oral estrogen therapy in postmenopausal women also lowers Lp(a), while transdermal estrogen has a more modest effect [23]. Including a note about current hormone therapy when ordering Lp(a) helps the interpreting clinician contextualize the result.

Imaging and Functional Tests to Consider After Lab Results

Lab values set the stage. Imaging tells you whether the disease process has already started. For patients with elevated Lp(a) and additional risk factors, a coronary artery calcium (CAC) score by non-contrast CT can reclassify risk. A CAC score of zero in an otherwise intermediate-risk patient is reassuring and may allow deferral of statin therapy [3]. A CAC score above 100 Agatston units strongly favors pharmacologic intervention.

The 2018 AHA/ACC guideline describes CAC scoring as the most useful test for refining risk when the decision about statin therapy is uncertain [3]. For a patient with elevated Lp(a) and a CAC score ≥100, the conversation shifts from "should we treat?" to "how aggressively should we treat?"

Carotid intima-media thickness (CIMT) is less well-validated for individual risk prediction and is not recommended as a routine screening tool by the USPSTF. It may have a role in research settings but adds little to clinical decision-making when CAC scoring is available.

What Cannot Lower Lp(a) and What Might

No FDA-approved drug specifically targets Lp(a) as of mid-2026. Statins do not lower Lp(a). Some data suggest statins may slightly increase Lp(a), though the clinical significance of this effect is debated [24]. Niacin lowers Lp(a) by roughly 20-30%, but the AIM-HIGH trial (N=3,414) showed no cardiovascular benefit from adding niacin to statin therapy, and the drug carries flushing and hepatotoxicity risks [25].

PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by approximately 20-30% as a secondary effect [10]. The FOURIER trial post-hoc analysis showed that patients with higher baseline Lp(a) derived greater absolute benefit from evolocumab, with a 2.49% absolute risk reduction in the highest Lp(a) quartile versus 0.95% in the lowest [26].

Two antisense and siRNA therapies are in Phase III trials. Pelacarsen (an antisense oligonucleotide targeting hepatic LPA mRNA) reduced Lp(a) by up to 80% in Phase II data [27]. The Lp(a)HORIZON trial (NCT04023552, N≈8,323) is evaluating whether that biochemical reduction translates to fewer cardiovascular events, with results expected in 2026-2027. Olpasiran, a small interfering RNA, reduced Lp(a) by more than 95% in the Phase II OCEAN(a)-DOSE trial [28]. Its Phase III cardiovascular outcomes trial (OCEAN(a) Outcomes) is also underway.

Dr. Sotirios Tsimikas, a professor of medicine at UC San Diego and a leading Lp(a) researcher, has stated: "For the first time, we have agents that can reduce Lp(a) by 80 to 95 percent. If the outcomes trials confirm benefit, Lp(a) will move from a risk marker to a treatable target" [29].

Putting the Panel Together: A Practical Ordering Guide

For a patient receiving their first Lp(a) measurement, the following paired labs cover the clinical ground most thoroughly:

Tier 1 (order for every patient)

• Lp(a) (reported in nmol/L preferred; mg/dL acceptable)
• Standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Apolipoprotein B
• High-sensitivity CRP
• Fasting glucose and HbA1c

Tier 2 (order when clinical context supports it)

• NMR lipoprotein subfractionation or ion-mobility testing
• Fasting insulin
• TSH
• Fibrinogen (if personal or family history of thrombosis)
• Homocysteine (if family history of premature CVD)

Tier 3 (imaging, ordered after labs are back)

• Coronary artery calcium score (if Lp(a) elevated and treatment decision is uncertain)

All Tier 1 tests can run from a single fasting blood draw. Adding Tier 2 markers requires no extra tubes in most reference labs. The cost of the full Tier 1 panel is typically covered by insurance when ordered with appropriate ICD-10 codes (E78.41 for elevated Lp(a), E78.5 for dyslipidemia, Z82.49 for family history of cardiovascular disease).

Lp(a) is measured once. The paired metabolic and inflammatory markers should be repeated annually, or more frequently if treatment changes are made. ApoB is the best single metric to track treatment response over time.